CLEC14A and colorectal carcinoma: In vivo Matrigel plug assays have shown that the addition of blocking CLEC14a mAb to human HCC, PDAC, CRC, and bevacizumab-adapted CRC cells led to significantly decreased MVD and decreased MVD more than bevacizumab treatment in the bevacizumab-resistant CRC cell line [107].